Beijing Scitop Bio-tech Co., Ltd. (SHE:300858)
China · Delayed Price · Currency is CNY 14.39
-0.38 (-2.57%)
Sep 2, 2026, 3:04 PM CST
Beijing Scitop Bio-tech Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 3,892 | 4,419 | 3,789 | 5,085 | 4,605 | 4,931 | |
Market Cap Growth | -23.11% | 16.62% | -25.49% | 10.44% | -6.62% | -1.34% |
Enterprise Value | 3,215 | 3,607 | 3,049 | 4,624 | 4,075 | 4,417 |
Last Close Price | 14.77 | 16.65 | 14.15 | 18.80 | 19.84 | 20.90 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | 48.84 | 46.75 | 40.16 | 54.40 | 41.90 | 45.02 |
Forward PE | - | 27.08 | 26.15 | 40.21 | 30.09 | 35.32 |
PS Ratio | 10.46 | 12.08 | 12.51 | 16.99 | 12.47 | 13.52 |
PB Ratio | 2.17 | 2.40 | 2.12 | 2.93 | 2.71 | 5.10 |
P/TBV Ratio | 2.25 | 2.48 | 2.18 | 3.03 | 2.81 | 5.41 |
P/FCF Ratio | - | - | - | - | 71.64 | 115.50 |
P/OCF Ratio | 36.81 | 35.80 | 26.66 | 47.41 | 31.02 | 44.72 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 8.64 | 9.86 | 10.07 | 15.45 | 11.04 | 12.11 |
EV/EBITDA Ratio | 33.35 | 34.29 | 32.12 | 55.80 | 32.58 | 42.25 |
EV/EBIT Ratio | 55.38 | 49.72 | 43.54 | 71.81 | 37.58 | 49.28 |
EV/FCF Ratio | - | - | - | - | 63.40 | 103.46 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
Debt / EBITDA Ratio | 0.04 | 0.03 | 0.04 | 0.14 | 0.06 | 0.08 |
Debt / FCF Ratio | - | - | - | - | 0.12 | 0.20 |
Net Debt / Equity Ratio | -0.38 | -0.45 | -0.46 | -0.47 | -0.68 | -0.58 |
Net Debt / EBITDA Ratio | -7.07 | -7.86 | -8.71 | -9.84 | -9.18 | -5.40 |
Net Debt / FCF Ratio | 10.97 | 4.79 | 11.92 | 11.45 | -17.87 | -13.23 |
Asset Turnover | 0.19 | 0.19 | 0.16 | 0.17 | 0.26 | 0.36 |
Inventory Turnover | 3.79 | 3.82 | 2.95 | 3.02 | 3.42 | 3.71 |
Quick Ratio | 4.04 | 7.05 | 9.23 | 15.26 | 14.83 | 11.09 |
Current Ratio | 4.55 | 7.66 | 9.93 | 16.30 | 15.56 | 12.05 |
Return on Equity (ROE) | 4.38% | 5.20% | 5.36% | 5.45% | 8.25% | 11.53% |
Return on Assets (ROA) | 1.83% | 2.31% | 2.35% | 2.23% | 4.79% | 5.49% |
Return on Invested Capital (ROIC) | 5.00% | 6.68% | 6.46% | 8.05% | 19.96% | 21.28% |
Return on Capital Employed (ROCE) | 3.20% | 3.80% | 3.80% | 3.70% | 6.40% | 9.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.01% | 2.14% | 2.49% | 1.84% | 2.39% | 2.22% |
FCF Yield | -1.58% | -3.91% | -1.83% | -1.40% | 1.40% | 0.87% |
Dividend Yield | 0.63% | 0.60% | 1.06% | 0.80% | 1.01% | 1.59% |
Payout Ratio | 50.41% | 41.82% | 41.89% | 56.38% | 67.76% | 75.33% |
Buyback Yield / Dilution | 1.37% | -0.17% | 1.87% | -19.09% | -1.00% | -16.50% |
Total Shareholder Return | 2.01% | 0.43% | 2.93% | -18.29% | 0.01% | -14.91% |